University Hospital of North Staffordshire
Welcome,         Profile    Billing    Logout  
 7 Trials 
13 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Davies, Simon J
StaN, NCT03672201: Standardizing Care for Neuropsychiatric Symptoms and Quality of Life in Dementia

Active, not recruiting
N/A
187
Canada
Non-Pharmacological Intervention, Behavioural Intervention, Pharmacological Intervention
Centre for Addiction and Mental Health, University of Calgary, Lawson Health Research Institute, Douglas Mental Health University Institute
Alzheimer's Disease, Alzheimer Dementia (AD), Aggression
03/23
12/24
PHOSPHATE, NCT03573089: Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease

Recruiting
N/A
3600
Europe, Canada, RoW
Liberal phosphate target, Intensive phosphate target
The University of Queensland, National Health and Medical Research Council, Australia, Applied Health Research Centre, Cambridge University Hospitals NHS Foundation Trust, University of Otago
Kidney Failure, Chronic, Hyperphosphatemia
12/27
12/28
NCT05943730: Validity of Measuring Preoperative Fitness Using Seismofit

Recruiting
N/A
143
Europe
Seismofit
Northumbria University, South Tees Hospitals NHS Foundation Trust, Sheffield Teaching Hospitals NHS Foundation Trust, York Teaching Hospitals NHS Foundation Trust, Ventriject, Denmark, Aalborg University
Preoperative Care, Validity
08/24
08/24
Lambie, Mark
Elixir, NCT03994471 / 2019-004183-21: Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.

Recruiting
3
170
Europe
XyloCore Low Strenght, XyloCore Medium Strenght, XyloCore High Strenght, XyloCore 0.7 or 1.5 or 2.0, 1.36%, 1.5%, 2.27%, 2.5%, 3.86%, 2.25% Glucose PD Solution, Physioneal 40 or 35, Fixioneal 40 or 35, Dianeal, Balance, Bicavera, Bicanova, Equibalance
Iperboreal Pharma Srl, Iperboreal Pharma Srl,
End Stage Renal Disease
12/24
12/24
Person, Contact
PATCH, NCT00303784 / 2005-001030-33: Prostate Adenocarcinoma TransCutaneous Hormones

Recruiting
3
2200
Europe
Goserelin, Zoladex, Estradiol, FemSeven
University College, London, Medical Research Council
Anemia, Cardiovascular Complications, Hot Flashes, Osteoporosis, Prostate Cancer
08/21
08/21
UKALL14, NCT01085617 / 2009-012717-22: Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Active, not recruiting
3
1033
NA
palifermin, rituximab, cyclophosphamide, cytarabine, daunorubicin hydrochloride, etoposide, fludarabine phosphate, imatinib mesylate, melphalan, mercaptopurine, methotrexate, nelarabine, pegaspargase, vincristine sulfate, allogeneic hematopoietic stem cell transplantation, total-body irradiation
University College, London
Leukemia, Mucositis, Oral Complications
12/24
12/25
STAMPEDE, NCT00268476: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy

Active, not recruiting
2/3
11992
Europe
Celecoxib, Celebrex, Docetaxel, Taxotere, Prednisolone, Prednisone, ADT, Androgen Deprivation Therapy, Zoledronic Acid, Zometa, Abiraterone, Zytiga, Radiotherapy to the prostate, RT, Enzalutamide, Xtandi, Metformin, Metformin Hydrochloride, Transdermal Oestradiol, Progynova TS
Medical Research Council
Prostate Cancer
03/26
12/30
NCT00589017: Tamoxifen in Treating Patients With Metastatic Bladder Cancer That Did Not Respond to Previous Chemotherapy

Recruiting
2
75
US, Europe
tamoxifen citrate, immunohistochemistry staining method, laboratory biomarker analysis
Baylor College of Medicine
Bladder Cancer
07/10
 
NCT03412643: Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling

Recruiting
2
64
US
Doxorubicin, Cyclophosphamide, Weekly Paclitaxel, Trastuzumab, Pertuzumab, Celcuity CELx HSF
NSABP Foundation Inc, Celcuity, LLC, Genentech, Inc.
HER2-negative Breast Cancer
10/23
10/23
PRISM, NCT03658525: Prostate Radiotherapy Integrated With Simultaneous MRI (The Study)

Recruiting
N/A
30
Europe
MR LINAC
Royal Marsden NHS Foundation Trust
Prostate Cancer
08/20
08/23
NCT06032663: Use of PET-MR in Head and Neck Cancer Patients - Diagnostic and Therapeutic Applications

Recruiting
N/A
10
Europe
PET-MRI
Sheffield Teaching Hospitals NHS Foundation Trust
Head and Neck Cancer
10/24
10/25
NCT01840293: Breast Cancer Proteomics and Molecular Heterogeneity

Recruiting
N/A
1780
Europe
Cancer Trials Ireland
Primary Breast Cancer, Recurrent/Metastatic Breast Cancer
12/29
01/38
Kalra, Seema
ChariotMS, NCT04695080 / 2018-005038-39: - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis

Recruiting
2/3
200
Europe
Cladribine (MAVENCLAD®), Placebo
Queen Mary University of London, National Institute for Health Research, United Kingdom, Merck Serono Limited, UK, Multiple Sclerosis Society of Great Britain & Northern Ireland, National Multiple Sclerosis Society, Barts & The London NHS Trust
Advanced Multiple Sclerosis, Progressive Multiple Sclerosis
12/24
12/27
Lucas, Joanne
No trials found

Download Options